United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole tablets are indicated for the treatment of: prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. fluconazole is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. coadministration of terfenadine is contraindicated in

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 50 mg - fluconazole tablets are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of candida urinary tract infections, peritonitis, and systemic candida infections including candidemia, disseminated candidiasis, and pneumonia. - cryptococcal meningitis. before prescribing fluconazole tablets for aids patients with cryptococcal meningitis, please see clinical studies section. studies comparing fluconazole tablets to amphotericin b in non-hiv infected patients have not been conducted. prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. fluconazole is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. coadministration of other drugs known to prolong the qt interval and which are metabolized via the enzyme cyp3a4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (see clinical pharmacology: drug interaction studies   and precautions. )

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 50 mg - fluconazole tablets are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of candida urinary tract infections, peritonitis, and systemic candida infections including candidemia, disseminated candidiasis, and pneumonia. - cryptococcal meningitis. before prescribing fluconazole tablets for aids patients with cryptococcal meningitis, please see clinical studies section. studies comparing fluconazole tablets to amphotericin b in non-hiv infected patients have not been conducted. prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. fluconazole is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. coadministration of other drugs known to prolong the qt interval and which are metabolized via the enzyme cyp3a4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (see clinical pharmacology: drug interaction studies and precautions. )

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - fluconazole-baxter intravenous infusion should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. vaginal candidiasis, when topical therapy has failed. 6. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - fluconazole-baxter intravenous infusion should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. vaginal candidiasis, when topical therapy has failed. 6. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - fluconazole-baxter intravenous infusion should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. vaginal candidiasis, when topical therapy has failed. 6. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 50 mg - fluconazole tablets are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of candida urinary tract infections, peritonitis, and systemic candida infections including candidemia, disseminated candidiasis, and pneumonia. - cryptococcal meningitis. before prescribing fluconazole tablets for aids patients with cryptococcal meningitis, please see clinical studies section. studies comparing fluconazole to amphotericin b in non-hiv infected patients have not been conducted. fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 150 mg - fluconazole tablets are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of candida  urinary tract infections, peritonitis, and systemic candida infections including candidemia, disseminated candidiasis, and pneumonia. - cryptococcal meningitis . before prescribing fluconazole tablets for aids patients with cryptococcal meningitis , please see clinical studies section. studies comparing fluconazole tablets to amphotericin b in non-hiv infected patients have not been conducted. prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. fluconazole tablets are contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing fluconazole tablets to patients with hypersensitivity to other azoles. coadministration of other drugs known to prolong the qt interval and which are metabolized via the enzyme cyp3a4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (see clinical pharmacology: drug interaction studies   and precautions .)

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 100 mg - fluconazole tablets are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of candida  urinary tract infections, peritonitis, and systemic candida infections including candidemia, disseminated candidiasis, and pneumonia. - cryptococcal meningitis . before prescribing fluconazole tablets for aids patients with cryptococcal meningitis , please see clinical studies section. studies comparing fluconazole tablets to amphotericin b in non-hiv infected patients have not been conducted. prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (sero

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 10 mg in 1 ml - fluconazole for oral suspension, usp is indicated for the treatment of: prophylaxis: fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. fluconazole for oral suspension usp is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. co-administration of te